uniQure NV (NASDAQ:QURE) – Research analysts at Jefferies Group lifted their Q3 2016 earnings per share estimates for shares of uniQure NV in a note issued to investors on Monday. Jefferies Group analyst E. Yang now forecasts that the firm will post earnings per share of ($0.96) for the quarter, up from their prior estimate of ($1.00). Jefferies Group currently has a “Hold” rating and a $8.00 target price on the stock. Jefferies Group also issued estimates for uniQure NV’s Q4 2016 earnings at ($0.99) EPS, FY2016 earnings at ($3.61) EPS, FY2017 earnings at ($2.28) EPS and FY2018 earnings at ($1.94) EPS.

A number of other equities analysts have also recently issued reports on the company. Leerink Swann restated a “positive” rating and set a $27.00 price target on shares of uniQure NV in a report on Tuesday, August 2nd. Zacks Investment Research upgraded uniQure NV from a “sell” rating to a “hold” rating in a report on Wednesday, September 21st. HC Wainwright initiated coverage on uniQure NV in a report on Thursday, August 4th. They issued a “buy” rating and a $21.00 target price on the stock. Piper Jaffray Cos. set a $16.00 target price on uniQure NV and gave the stock a “buy” rating in a report on Friday, August 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $12.00 target price (down from $20.00) on shares of uniQure NV in a report on Tuesday, November 15th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $22.70.

Earnings History and Estimates for uniQure NV (NASDAQ:QURE)

COPYRIGHT VIOLATION NOTICE: “Q3 2016 Earnings Estimate for uniQure NV Issued By Jefferies Group (QURE)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/26/q3-2016-earnings-estimate-for-uniqure-nv-issued-by-jefferies-group-qure.html.

uniQure NV (NASDAQ:QURE) opened at 6.85 on Thursday. uniQure NV has a 52 week low of $6.41 and a 52 week high of $22.00. The stock has a 50 day moving average of $7.17 and a 200-day moving average of $8.54. The firm’s market cap is $172.13 million.

COPYRIGHT VIOLATION NOTICE: “Q3 2016 Earnings Estimate for uniQure NV Issued By Jefferies Group (QURE)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/26/q3-2016-earnings-estimate-for-uniqure-nv-issued-by-jefferies-group-qure.html.

Several large investors have recently made changes to their positions in QURE. JPMorgan Chase & Co. raised its stake in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in shares of uniQure NV during the third quarter valued at about $111,000. TFS Capital LLC raised its stake in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares in the last quarter. Princeton Alpha Management LP acquired a new stake in shares of uniQure NV during the second quarter valued at about $120,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of uniQure NV during the second quarter valued at about $122,000. 28.99% of the stock is owned by hedge funds and other institutional investors.

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.